[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-covid\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-covid":87},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100620581","phase-3-selective-serotonin-reuptake-inhibitors-in-post-covid-after-covid-19-100620581",false,"NCT07359482","sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19","sElective Serotonin reuPtake inhibitoRs In posT-covid: ESPRIT","ESPRIT","Inclusion Criteria:\n\n* Adults aged 18 to 70 years\n* Severely fatigued (CIS fatigue score ≥ 35) at screening\n* Fatigue started\u002Fincreased significantly after Covid-19 (self-declared)\n* Fatigue symptoms must be present for at least 3 months following the acute infection.\n* Self-reported confirmation of having a SARS-CoV-2 infection by: Positive SARS-CoV-2 nucleic acid amplification test (NAAT), such as PCR; Positive SARS-CoV-2 rapid diagnostic test, including home-administered tests; COVID-19 diagnosis by a medical specialist (GP or in-hospital), based on the above or other clinical test or assessments. The above information will not be verified in medical records.\n* Command of Dutch or English language to complete questionnaires\n* Able to participate in video calling.\n* Willing and able to provide informed consent\n* Allowing the trial team to exchange medical information that is relevant for the participants' safety and trial assessments with their GP and pharmacy.\n\nExclusion Criteria:\n\n* Use of medication with interaction with fluvoxamine that cannot be discontinued\n* Hospitalized in the acute phase of Covid-19\n* Psychiatric\u002Fsomatic disorders that could explain the severity of fatigue\n* Neurodegenerative disorders (i.e. M Parkinson, Multiple sclerosis, M Alzheimer)\n* Suicidality (current or recent) (according to WHO suicide screener)\n* Starting or started with other medication intended to reduce post-covid symptoms during the last 2 months\n* Pregnancy (a positive urine or serum pregnancy test) or unwilling to use standard contraception\n* Brugada- or Long QT interval syndrome\n* epilepsy, porphyria, history of severe liver impairment\n* known allergies to fluvoxamine or placebo\u002Fexcipients\n* known current alcohol or drug use problems.\n* Bleeding disorders and past medical history of bleeding gastric or duodenal ulcers or other significant bleeding disorders\n* claustrophobia (optional MRI substudy)\n* having metal implants (optional MRI substudy)\n* inability to lay still for 45 minutes (optional MRI substudy)\n* Neurotrauma\u002F large stroke or brain abnormalities interfering with image analyses (optional MRI substudy)\n* Inability to come to the Amsterdam UMC (optional MRI substudy).","ALL","18 Years","70 Years",{"count":21,"type":22},160,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Fatigue, cognitive problems, post-exertional malaise (PEM) and postural orthostatic tachycardia syndrome (POTS) are common and debilitating symptoms after COVID-19. The pathophysiology of post-COVID is not well understood and there is no established biomedical treatment. Treatment options for post-COVID are thus much needed.\n\nA promising candidate intervention is fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), that may reduce post-COVID symptoms because of its regulatory effect on the (neuro) immune system, the hypothalamic-pituitary-adrenal (HPA) axis and the tryptophan system. The investigators will randomize 160 participants to either fluvoxamine or placebo for 12 weeks.\n\nThe investigators will use advanced functional neuroimaging techniques during cognitive challenge (optional substudy) and plasma biomarkers (inflammatory markers, cortisol, serotonin, IDO-2 activity), to facilitate identifying potential mechanistic pathways of post -COVID treatment.",[28,29,30],"Post-COVID","POST-Covid 19","Post-COVID Conditions",[32,33,34,35],"post-COVID","fluvoxamine","fatigue","biomarkers","RECRUITING","2026-06-08",{"date":39,"type":40},"2026-06-09","ACTUAL",{"date":42,"type":40},"2026-06-04",{"date":44,"type":22},"2028-05-01",{"name":46,"class":47},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":68,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":48},"100585068","act-for-mental-health-in-neurological-disorders-100585068","NCT06897553","ACT for Mental Health in Neurological Disorders","Acceptance and Commitment Therapy- Based Group Therapy for Mental Health in Neurological Disorders","Inclusion Criteria:\n\n* Value above a cut-off of the DASS-21 subscales (depression \\> 10, anxiety \\> 6, and stress \\> 10)\n* Sufficient cognition and language ability (clinical rating)\n* Sufficient therapy motivation (clinical rating)\n\nExclusion Criteria:\n\n* Behavioral disorders (e.g., high irritability or apathy in clinical rating)\n* Other severe mental disorder (dementia, psychosis, personality disorders, intellectual disability)\n* Simultaneous psychotherapy or neuropsychological therapy",{"count":57,"type":22},44,[59],"NA","The goal of this clinical trial is to examine the efficacy of this manual for mental health in people with mixed neurological disorders, including post-COVID. These conditions are often associated with cognitive impairment, which may hamper the effects of psychoterapy. Executive functioning and especially the ability to abstract thinking may be useful for individuals using Acceptance and Commitment Therapy. Therefore, the main questions research questions are:\n\n* Is this intervention effective in improving mental health?\n* Do executive functions predict the extent of social participation and mental health at the end of therapy? Participants will take part in 8 weekly group therapy sessions of 100 minutes each.",[62,63,64,65,66,67,28],"Neurological Disorders","Mental Health","Executive Function (Cognition)","Depression\u002FAnxiety","Stress","Brain Injury",[69,70,71,72,73,74,75,76,77,28],"Acceptance and Commitment Therapy (ACT)","group therapy","neurological disorders","brain injury","anxiety","stress","depression","executive functioning","abstraction ability","2025-03-25",{"date":80,"type":40},"2025-03-27",{"date":82,"type":40},"2024-12-01",{"date":84,"type":22},"2026-12-31",{"name":86,"class":47},"Bielefeld University","Post COVID"]